

MASTERING THE SYSTEMATIC REVIEW

DAY - 1

1) BASICS ABOUT RESEARCH

2) PRISMA

3) PICO/ PECO FRAMEWORK

4) INTRODUCTION TO PROSPERO

5) SEARCH STRATEGY

WHY NEED RESEARCH?

WHAT IS RESEARCH?

MAJOR CATEGORIES OF RESEARCH STUDIES



QUANTITATIVE

QUALITATIVE

QUALITATIVE

OPINIONS

EXPERIENCES

STUDIES INCLUDED
EXAMPLES:

- INTERVIEWS
- FOCUS GROUPS

QUANTITATIVE

NUMBERS

MEASURED
VARIABLES

STATISTICAL
ANALYSIS

STUDIES INCLUDED
EXAMPLES:

- SURVEYS
- EXPERIMENTS
- CLINICAL TRIALS



NOW AS A BEGINNER
WHICH STUDY TYPE YOU
SHOULD CHOOSE TO START YOUR
RESEARCH JOURNEY???



QUANTITATIVE

QUALITATIVE

NOW AS A BEGINNER
WHICH STUDY TYPE YOU
SHOULD CHOOSE TO START YOUR
RESEARCH JOURNEY???



QUANTITATIVE



QUALITATIVE



QUANTITATIVE

WHY QUANTITATIVE STUDY IS BETTER TO START WITH AS A BEGINNER COMPARED TO QUALITATIVE STUDY??



QUALITATIVE

1

BUILDS A FOUNDATION IN EVIDENCE-BASED MEDICINE

You learn how most real-world medical decisions are made.

2

EASIER TO LEARN, STANDARDIZED METHODOLOGY

Perfect for students who need structure while building confidence in research.

3

BROADER ACCEPTANCE FOR PUBLISHING

Easier to publish, present, and include in applications.

4

DEVELOPS STATISTICAL AND ANALYTICAL SKILLS EARLY

These are transferable skills you'll use throughout your career.

5

EASIER TO START SMALL (E.G., SURVEYS, SECONDARY DATA)

Quantitative studies are more manageable for individual or group student projects

COMPARISON!!!!

QUANTITATIVE FIRST

- 1 OBJECTIVE & MEASURABLE
- 2 TEACHES STATISTICAL ANALYSIS
- 3 EASIER TO PUBLISH
- 4 BETTER FOR BEGINNERS

QUALITATIVE LATER

- 1 CONTEXTUAL & DESCRIPTIVE
- 2 TEACHES INTERPRETIVE SKILLS
- 3 HARDER TO GENERALIZE
- 4 NEEDS ADVANCED UNDERSTANDING

IN QUANTITATIVE-
WHICH STUDY IS BEST
TO START WITH???

“BEST TO LEARN BEFORE
YOU LEAD”



AT NEXASEARCH- STARTING OUR RESEARCH JOURNEY BY...

“REVIEW STUDIES”

WHY??

“NO NEED FOR
PATIENT INTERACTION
OR LAB ACCESS”

“HELPS IDENTIFY
RESEARCH GAPS”

BUILDS STRONG
RESEARCH
FUNDAMENTALS

“ENHANCES
LITERATURE
NAVIGATION SKILLS”

“DEVELOPS CRITICAL
THINKING”

“INCREASES FAMILIARITY
WITH RESEARCH
METHODOLOGY”

“REVIEW STUDIES”


TYPES

LITERATURE
REVIEW

SYSTEMATIC
REVIEW

“SUBJECTIVE SUMMARY”
OF EXISTING KNOWLEDGE
BASED ON SELECTED
SOURCES

“OBJECTIVE, REPRODUCIBLE
SYNTHESIS” OF ALL
RELEVANT EVIDENCE USING A
PREDEFINED METHOD.



INTRODUCTION TO **SYSTEMATIC REVIEWS**

1.1 DEFINITION

A SYSTEMATIC REVIEW IS A CLEAR AND ORGANIZED WAY OF COLLECTING AND ANALYZING INFORMATION FROM MANY DIFFERENT STUDIES ON A SPECIFIC TOPIC OR QUESTION. IT FOLLOWS A SET PLAN TO FIND, CHOOSE, AND CAREFULLY REVIEW EACH STUDY TO MAKE SURE THE RESULTS ARE TRUSTWORTHY. THE GOAL IS TO GIVE A COMPLETE AND UNBIASED SUMMARY OF WHAT RESEARCH SAYS ABOUT THAT TOPIC.

ANALOGY

YOUTUBE
(RANDOM, ALGORITHM-DRIVEN)



NETFLIX PLAYLIST
(CURATED, STRUCTURED)



1.2 PURPOSE

1. **SUMMARIZE EVIDENCE:** COMBINE FINDINGS FROM MULTIPLE STUDIES TO PROVIDE A CLEAR OVERVIEW OF WHAT IS KNOWN ABOUT A TOPIC.
2. **IDENTIFY GAPS:** HIGHLIGHT AREAS WHERE EVIDENCE IS LACKING OR INCONSISTENT, GUIDING FUTURE RESEARCH.
3. **INFORM DECISION-MAKING:** SUPPORT EVIDENCE-BASED PRACTICE, POLICY, AND CLINICAL GUIDELINES BY PROVIDING ROBUST CONCLUSIONS.
4. **REDUCE BIAS:** USE RIGOROUS, TRANSPARENT METHODS TO MINIMIZE SUBJECTIVITY AND ENSURE RELIABILITY.
5. **RESOLVE CONTROVERSIES:** ADDRESS CONFLICTING RESULTS FROM INDIVIDUAL STUDIES BY SYNTHESIZING DATA SYSTEMATICALLY.
6. **IMPROVE EFFICIENCY:** SAVE TIME AND RESOURCES BY CONSOLIDATING EXISTING RESEARCH RATHER THAN CONDUCTING NEW PRIMARY STUDIES.

TIMELINE OF SR IMPACT ON **GLOBAL HEALTH POLICIES**

1.3 KEY FEATURES OF SYSTEMATIC REVIEWS

- **PROTOCOL-DRIVEN:** FOLLOWS A PREDEFINED PLAN (E.G., PRISMA-P CHECKLIST) FOR TRANSPARENCY AND REPRODUCIBILITY.
- **COMPREHENSIVE SEARCH:** SEARCHES MULTIPLE DATABASES AND GREY LITERATURE TO ENSURE ALL RELEVANT STUDIES ARE INCLUDED.
- **CRITICAL APPRAISAL:** USES TOOLS LIKE ROB 2 TO ASSESS STUDY QUALITY AND MINIMIZE BIAS.
- **STRUCTURED SYNTHESIS:** COMBINES FINDINGS QUALITATIVELY OR QUANTITATIVELY (E.G., META-ANALYSIS).
- **TRANSPARENCY:** DOCUMENTS ALL STEPS FOR CLARITY AND REPLICABILITY.

1.4 TYPES OF EVIDENCE SYNTHESSES

- **SYSTEMATIC REVIEW:**

FOCUS: NARROW, ANSWER-SPECIFIC QUESTIONS (E.G., "DOES ASPIRIN REDUCE STROKE RISK IN AF PATIENTS?").

METHODS: META-ANALYSIS, GRADE FOR EVIDENCE CERTAINTY.

EXAMPLE: COCHRANE REVIEWS.

- **SCOPING REVIEW:**

FOCUS: BROAD MAPPING OF EVIDENCE (E.G., "WHAT INTERVENTIONS EXIST FOR DIABETIC FOOT ULCERS?").

USE: IDENTIFIES RESEARCH GAPS, GUIDES FUTURE SRS.

- **NARRATIVE REVIEW:**

FOCUS: EXPERT OPINION, NO FORMAL METHODOLOGY.

LIMITATIONS: HIGH RISK OF SELECTION BIAS.

- **RAPID REVIEW:**

FOCUS: ACCELERATED SYNTHESIS FOR URGENT POLICY DECISIONS (E.G., PANDEMICS).

TRADE-OFF: LIMITED SEARCH DEPTH.

Q&A TIME!!!

**WHEN SHOULD I DO A
SCOPING REVIEW
INSTEAD OF A
SYSTEMATIC REVIEW ?**

ANSWER!!!



USE A SCOPING REVIEW WHEN THE TOPIC IS BROAD AND YOU WANT TO MAP EXISTING EVIDENCE RATHER THAN ANSWER A SPECIFIC QUESTION.

Q&A TIME!!!

**HOW IS A SCOPING
REVIEW DIFFERENT
FROM A LITERATURE
REVIEW?**

ANSWER!!!



**A SCOPING REVIEW FOLLOWS A
STRUCTURED METHODOLOGY,
WHILE A LITERATURE REVIEW IS
OFTEN LESS FORMAL.**

PRISMA
PRISMA
PRISMA
PRISMA
PRISMA

2.1 WHAT IS PRISMA?

- **PRISMA** (PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES) IS AN EVIDENCE-BASED FRAMEWORK FOR TRANSPARENTLY REPORTING SYSTEMATIC REVIEWS AND META-ANALYSES.
- **PURPOSE:** ENSURES CLARITY, REPRODUCIBILITY, AND COMPLETENESS IN REPORTING.
- **COMPONENTS:**
 - PRISMA CHECKLIST: **27-ITEM CHECKLIST FOR REPORTING.**
 - PRISMA FLOW DIAGRAM: VISUALIZES STUDY SELECTION PROCESS.
- **USE:** WIDELY ADOPTED IN HEALTHCARE, SOCIAL SCIENCES, AND OTHER FIELDS.


2.2 PRISMA FLOW CHART

- **PURPOSE:** TRACKS THE STUDY SELECTION PROCESS FROM IDENTIFICATION TO INCLUSION.
- **STAGES:**
 1. **IDENTIFICATION:** RECORDS FOUND THROUGH DATABASES AND OTHER SOURCES.
 2. **SCREENING:** TITLES/ABSTRACTS SCREENED FOR RELEVANCE.
 3. **ELIGIBILITY:** FULL-TEXT ARTICLES ASSESSED FOR INCLUSION.
 4. **INCLUDED:** STUDIES SELECTED FOR REVIEW.

PRISMA FLOW CHART



**SHOWS WHAT
YOU HAVE
EXCLUDED AND
INCLUDED IN
YOUR STUDY
BASED ON
CRITERIAS YOU
SETTED.**



2.3 PRISMA CHECKLIST

- **PURPOSE:** ENSURES ALL CRITICAL ASPECTS OF A SYSTEMATIC REVIEW ARE REPORTED.
- **KEY SECTIONS:**
 1. **TITLE:** CLEAR IDENTIFICATION AS A SYSTEMATIC REVIEW.
 2. **ABSTRACT:** STRUCTURED SUMMARY.
 3. **METHODS:** PROTOCOL, SEARCH STRATEGY, DATA EXTRACTION, AND ANALYSIS.
 4. **RESULTS:** STUDY SELECTION, CHARACTERISTICS, AND SYNTHESIS.
 5. **DISCUSSION:** INTERPRETATION AND LIMITATIONS.
- **WEBSITE:** [PRISMA-STATEMENT.ORG](https://prisma-statement.org)



Expanded Checklist

Q&A TIME!!!

**WHY DOES PRISMA
MATTER IN
PUBLISHING
SYSTEMATIC
REVIEWS?**



ANSWER!!!



MOST JOURNALS REQUIRE IT FOR SUBMISSION.

WHY??



BECAUSE IT ENSURES COMPLETENESS, TRANSPARENCY, AND MINIMIZES BIAS IN PUBLISHED REVIEWS.

Q&A TIME!!!

WHY IS **PRISMA**
DIFFERENT FROM
OTHER GUIDELINES
LIKE **CONSORT** OR
STROBE ?

ANSWER!!!



**PRISMA IS SPECIFIC TO
SYSTEMATIC REVIEWS AND META-
ANALYSES.**

WHY??



**OTHER GUIDELINES FOCUS ON
DIFFERENT STUDY TYPES (E.G.,
TRIALS OR OBSERVATIONAL
STUDIES), WHILE PRISMA FITS
REVIEWS BEST.**

Q&A TIME!!!

ANSWER!!!

**Your review
may lack
transparency**

**WHAT IF I
DIDN'T
FOLLOWED THE
PRISMA?**

ANSWER!!!

**You may miss
key steps in
review
methodology**

ANSWER!!!

**Lack of
credibility
among peers
and mentors**

PICO FRAMEWORK
PICO FRAMEWORK
PICO FRAMEWORK
PICO FRAMEWORK
PICO FRAMEWORK

2 SET OF FRAMEWORK TO WORK WITH...



```
graph TD; A[2 SET OF FRAMEWORK TO WORK WITH...] --> B((PICO FRAMEWORK)); A --> C((PECO FRAMEWORK));
```

**PICO
FRAMEWORK**

**PECO
FRAMEWORK**

PICO

KS

PECO

P

POPULATION

I

INTERVENTION

C

COMPARISON

O

OUTCOME

P

POPULATION

E

EXPOSURE

C

COMPARISON

O

OUTCOME

3.1 PICO FRAMEWORK

- **DEFINITION:** PICO IS A STRUCTURED FRAMEWORK USED TO DEFINE A CLEAR AND FOCUSED CLINICAL OR RESEARCH QUESTION.
- **COMPONENTS:**
 - **POPULATION:** THE SPECIFIC GROUP OF INTEREST (E.G., ADULTS WITH HYPERTENSION).
 - **INTERVENTION:** THE TREATMENT OR EXPOSURE BEING STUDIED (E.G., LOW-SODIUM DIET).
 - **COMPARISON:** THE ALTERNATIVE OR CONTROL (E.G., STANDARD DIET).
 - **OUTCOME:** THE MEASURABLE RESULT (E.G., BLOOD PRESSURE REDUCTION).
 - **USE CASE:** HELPS REFINE RESEARCH QUESTIONS FOR SYSTEMATIC REVIEWS, CLINICAL TRIALS, AND EVIDENCE-BASED PRACTICE.

3.2 PECO FRAMEWORK

- **DEFINITION:** AN ADAPTATION OF PICO FOR OBSERVATIONAL STUDIES, FOCUSING ON EXPOSURE INSTEAD OF INTERVENTION.
- **COMPONENTS:**
- **POPULATION:** THE GROUP BEING STUDIED (E.G., URBAN RESIDENTS).
- **EXPOSURE:** THE ENVIRONMENTAL OR RISK FACTOR (E.G., AIR POLLUTION).
- **COMPARISON:** THE UNEXPOSED OR CONTROL GROUP (E.G., LOW-POLLUTION AREAS).
- **OUTCOME:** THE HEALTH EFFECT (E.G., ASTHMA EXACERBATIONS).
- **EXAMPLE:** PECO FOR "IMPACT OF PM2.5 ON LUNG HEALTH."



4 COMMON PITFALLS IN FRAMING RESEARCH QUESTIONS:

1 BROAD POPULATION

2 VAGUE OUTCOMES

3 UNCLEAR INTERVENTIONS/EXPOSURES

4 MISSING COMPARISON

PITFALL 1 - BROAD POPULATION

- **ISSUE:** A POORLY DEFINED POPULATION LEADS TO HETEROGENEOUS RESULTS AND UNCLEAR APPLICABILITY.
- **EXAMPLES:**
 - "CANCER PATIENTS" → TOO GENERAL.
 - "ELDERLY INDIVIDUALS" → AGE RANGE NOT SPECIFIED.
 - "CHILDREN WITH INFECTIONS" → TYPE OF INFECTION UNCLEAR.
- **SOLUTIONS:**
 - SPECIFY SUBGROUPS, E.G., "STAGE III COLORECTAL CANCER PATIENTS."
 - DEFINE DEMOGRAPHICS, E.G., "ADULTS AGED 65-75 WITH TYPE 2 DIABETES."
 - NARROW BY CONDITION, E.G., "CHILDREN WITH BACTERIAL PNEUMONIA."

PITFALL 2 - VAGUE OUTCOMES

- **ISSUE:** BROAD OR NON-SPECIFIC OUTCOMES MAKE IT DIFFICULT TO MEASURE RESULTS EFFECTIVELY.
- **EXAMPLES:**
 - "IMPROVES HEALTH" → TOO BROAD.
 - "REDUCES SYMPTOMS" → UNCLEAR WHICH SYMPTOMS.
 - "ENHANCES QUALITY OF LIFE" → NOT MEASURABLE.
- **SOLUTIONS:**
 - USE SPECIFIC, VALIDATED TOOLS LIKE "SF-36 SCORE IMPROVEMENT."
 - DEFINE MEASURABLE OUTCOMES LIKE "REDUCTION IN SYSTOLIC BLOOD PRESSURE BY 10 MMHG."
 - SPECIFY TIMEFRAMES, E.G., "IMPROVEMENT IN PAIN SCORES AT 6 WEEKS."

PITFALL 3 - UNCLEAR INTERVENTIONS/EXPOSURES

- **ISSUE:** AMBIGUOUS INTERVENTIONS OR EXPOSURES MAKE IT HARD TO REPLICATE OR COMPARE STUDIES.
- **EXAMPLES:**
 - "EXERCISE" → TYPE, DURATION, AND FREQUENCY NOT DEFINED.
 - "DIETARY CHANGES" → SPECIFIC DIET NOT MENTIONED.
 - "MEDICATION" → DRUG NAME AND DOSAGE UNCLEAR.
- **SOLUTIONS:**
 - DEFINE INTERVENTIONS PRECISELY, E.G., "30 MINUTES OF MODERATE AEROBIC EXERCISE, 5 TIMES A WEEK."
 - SPECIFY DETAILS, E.G., "MEDITERRANEAN DIET FOR 12 WEEKS."
 - INCLUDE DOSAGES, E.G., "500 MG OF METFORMIN TWICE DAILY."


PITFALL 4 - MISSING COMPARISON

- **ISSUE:** WITHOUT A COMPARISON GROUP, IT'S IMPOSSIBLE TO ASSESS THE EFFECTIVENESS OF AN INTERVENTION.
- **EXAMPLES:**
 - "EFFECT OF YOGA ON STRESS" → NO COMPARISON GROUP.
 - "IMPACT OF AIR POLLUTION ON LUNG HEALTH" → NO LOW-POLLUTION CONTROL.
 - "BENEFITS OF A NEW DRUG" → NO PLACEBO OR STANDARD TREATMENT GROUP.
- **SOLUTIONS:**
 - ALWAYS INCLUDE A COMPARISON, E.G., "STANDARD CARE" OR "PLACEBO."
 - DEFINE CONTROL GROUPS CLEARLY, E.G., "LOW-POLLUTION URBAN AREAS."
 - USE ACTIVE COMPARATORS, E.G., "CURRENT STANDARD THERAPY."

PROSPERO
PROSPERO
PROSPERO
PROSPERO
PROSPERO

4. WHAT IS PROSPERO?

- **DEFINITION:** PROSPERO IS AN INTERNATIONAL DATABASE FOR REGISTERING SYSTEMATIC REVIEW PROTOCOLS.
- **PURPOSE:** PROMOTES TRANSPARENCY, REDUCES DUPLICATION, AND IMPROVES THE QUALITY OF SYSTEMATIC REVIEWS.
- **SCOPE:** ACCEPTS PROTOCOLS FOR REVIEWS OF INTERVENTIONS, DIAGNOSTICS, PROGNOSTICS, AND MORE.
- **MANAGED BY:** CENTRE FOR REVIEWS AND DISSEMINATION (CRD), UNIVERSITY OF YORK, UK.
- **WEBSITE**– (WWW.CRD.YORK.AC.UK/PROSPERO).



WHY IT MATTERS TO LEARN ABOUT PROSPERO BEFORE YOU START A SYSTEMATIC REVIEW?

WE'RE NOT REGISTERING ANYTHING TODAY!!!

Because before even forming your final research question, you need to ask:
Has someone already done a similar review ?

This is where PROSPERO helps:

- ➔ To **avoid duplication**
- ➔ To **get inspiration**- Looking at how other researchers framed similar topics helps you refine your own question.
- ➔ To **avoid duplication**
- ➔ To **strengthen your research question**

W
A
S
O
R
E

WHAT YOU WILL LEARN ABOUT PROSPERO IN WORKSHOP!!!



```
graph TD; A[WHAT YOU WILL LEARN ABOUT PROSPERO IN WORKSHOP!!!] --> B[HOW TO SEARCH PROSPERO?]; A --> C[HOW TO BUILD A REFINED, POWERFUL RESEARCH QUESTION?]; A --> D[HOW TO USE RESULTS TO SHAPE YOUR STRATEGY?];
```

**HOW TO
SEARCH
PROSPERO?**

**HOW TO
BUILD A
REFINED,
POWERFUL
RESEARCH
QUESTION?**

**HOW TO USE
RESULTS TO
SHAPE YOUR
STRATEGY?**

SEARCH STRATEGY
SEARCH STRATEGY
SEARCH STRATEGY
SEARCH STRATEGY
SEARCH STRATEGY





5.1 SEARCH STRATEGY – THE HEART OF A SYSTEMATIC REVIEW

“IF YOUR SEARCH IS WEAK, YOUR REVIEW WILL BE INCOMPLETE”

1) WHAT IS A SEARCH STRATEGY?

A search strategy is a step-by-step plan to find all relevant studies on your research question — in a systematic, unbiased, and reproducible way.

2) WHY IS IT SO IMPORTANT?

-  Ensures you find all existing evidence — not just what pops up on Google.
-  Helps avoid selection bias.
-  Makes your review reproducible — others should be able to follow your method.
-  Gives credibility to your work — good journals look at your strategy.

5.2 KEY COMPONENTS OF SEARCH STRATEGY

ELEMENT

DESCRIPTION

- | | | | |
|---|-----------------------|---|--|
| 1 | Research Question | → | Must be well-defined (usually in PICO/PECO format) |
| 2 | Databases | → | Where you'll search (e.g., PubMed, Scopus, Cochrane, Embase) |
| 3 | Keywords & MeSH Terms | → | Combine free text (keywords) + standardized terms (like "Myocardial Infarction" in MeSH) |
| 4 | Boolean Operators | → | Use AND, OR, NOT to connect keywords logically |
| 5 | Limits/Filters | → | Set date range, age group, study type, language, etc. |
| 6 | Documentation | → | Keep a full record of search terms, databases, date of search |

5.3 WHERE TO SEARCH? – COMMON DATABASES

DATABASE

BEST FOR

- | | |
|-------------------------|---|
| 1 PubMed | → Biomedical literature |
| 2 Cochrane Library | → Systematic reviews and trials |
| 3 Keywords & MeSH Terms | → Broad research coverage |
| 4 Scopus | → Cross-disciplinary sources |
| 5 Web of Science | → Drug & pharmacology-heavy studies |
| 6 Embase | → Grey literature (but less systematic) |



Thank you for having you guys!!!

**SEE YOU AT
WORKSHOP!!!**



5.3 REGISTRATION STEPS

- STEP 1: DRAFT A CLEAR PICO/PECO QUESTION.
- STEP 2: DEFINE INCLUSION/EXCLUSION CRITERIA.
- STEP 3: SUBMIT TO PROSPERO (INCLUDE SCREENSHOTS OF THE SUBMISSION INTERFACE).
- STEP 4: REVISE BASED ON PEER COMMENTS AND FINALIZE THE PROTOCOL.



**Q: CAN I START MY REVIEW BEFORE
PROSPERO REGISTRATION?**

**A: IT'S NOT RECOMMENDED—JOURNALS MAY
REJECT YOUR PAPER.**



PROTOCOL DEVELOPMENT
PROTOCOL DEVELOPMENT
PROTOCOL DEVELOPMENT
PROTOCOL DEVELOPMENT
PROTOCOL DEVELOPMENT



6.1 (PRISMA-P)

WHAT IS PRISMA-P?

- DEFINITION: PRISMA-P (PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEW AND META-ANALYSIS PROTOCOLS) IS A CHECKLIST FOR DEVELOPING SYSTEMATIC REVIEW PROTOCOLS.
- PURPOSE: ENSURES PROTOCOLS ARE COMPREHENSIVE, TRANSPARENT, AND REPRODUCIBLE.
- USE CASE: REQUIRED FOR PROSPERO REGISTRATION AND JOURNAL SUBMISSIONS.
- VISUAL: PRISMA-P CHECKLIST ICON OR LOGO.



6.2 PROTOCOL COMPONENTS

- RATIONALE:
 - EXPLAIN WHY THE RESEARCH QUESTION MATTERS.
 - EXAMPLE: "RISING GLOBAL DIABETES RATES NECESSITATE A REVIEW OF SGLT2 INHIBITORS FOR HEART FAILURE."
- ELIGIBILITY CRITERIA:
 - INCLUSION: RCTS, ADULTS, ENGLISH LANGUAGE.
 - EXCLUSION: ANIMAL STUDIES, EDITORIALS, NON-PEER-REVIEWED ARTICLES.
- SEARCH STRATEGY:
 - DATABASES: PUBMED, EMBASE, COCHRANE.
 - KEYWORDS: "SGLT2 INHIBITORS," "HEART FAILURE," "HOSPITALIZATION."
 - FILTERS: PUBLICATION DATE, LANGUAGE, STUDY DESIGN.
- RISK OF BIAS TOOLS:
 - SPECIFY TOOLS LIKE ROB 2 FOR RANDOMIZED TRIALS.
- DATA SYNTHESIS PLAN:
 - DESCRIBE METHODS FOR QUALITATIVE OR QUANTITATIVE SYNTHESIS (E.G., META-ANALYSIS).



6.3 CHECKLIST

PRISMA-P CHECKLIST HIGHLIGHTS

- ITEM 7: "DESCRIBE ALL ELIGIBILITY CRITERIA IN DETAIL."
- ITEM 12: "SPECIFY RISK OF BIAS TOOLS (E.G., ROB 2)."
- ITEM 15: "OUTLINE DATA EXTRACTION METHODS."
- ITEM 17: "DETAIL STATISTICAL METHODS FOR META-ANALYSIS (IF APPLICABLE)."
- VISUAL: TABLE WITH KEY PRISMA-P ITEMS AND EXAMPLES.



6.4 EXAMPLES

CASE STUDY: PUBLISHED PROTOCOL

- EXAMPLE: "ANTICOAGULATION IN COVID-19: A COCHRANE PROTOCOL."
 - RATIONALE: HIGH THROMBOSIS RISK IN COVID-19 PATIENTS.
 - ELIGIBILITY: RCTS ON ANTICOAGULATION IN HOSPITALIZED ADULTS.
 - SEARCH: MEDLINE, CENTRAL, CLINICAL TRIAL REGISTRIES.
 - OUTCOMES: MORTALITY, BLEEDING EVENTS, ICU ADMISSION.
- COMMON REVISIONS REQUESTED BY PROSPERO:
 - CLARIFYING OUTCOMES (E.G., "SPECIFY PRIMARY VS. SECONDARY OUTCOMES").
 - EXPANDING SEARCH TERMS (E.G., "INCLUDE SYNONYMS FOR ANTICOAGULANTS").
 - JUSTIFYING EXCLUSION CRITERIA (E.G., "WHY EXCLUDE NON-ENGLISH STUDIES?").



6.5 COMMON PITFALLS IN PROTOCOL DEVELOPMENT

- VAGUE OBJECTIVES:
 - EXAMPLE: "TO REVIEW TREATMENTS FOR DIABETES."
 - SOLUTION: SPECIFY FOCUS, E.G., "TO ASSESS THE EFFICACY OF SGLT2 INHIBITORS IN REDUCING HEART FAILURE HOSPITALIZATIONS."
- INCOMPLETE SEARCH STRATEGY:
 - EXAMPLE: SEARCHING ONLY ONE DATABASE.
 - SOLUTION: INCLUDE MULTIPLE DATABASES (PUBMED, EMBASE, COCHRANE).
- UNCLEAR ELIGIBILITY CRITERIA:
 - EXAMPLE: "INCLUDE RELEVANT STUDIES."
 - SOLUTION: DEFINE CRITERIA PRECISELY, E.G., "RCTS PUBLISHED IN ENGLISH BETWEEN 2010–2023."
- VISUAL: CHECKLIST FOR AVOIDING PITFALLS.

6.6 TIPS FOR SUCCESSFUL PROTOCOL DEVELOPMENT

- FOLLOW PRISMA-P GUIDELINES: USE THE CHECKLIST TO ENSURE COMPLETENESS.
- SEEK PEER FEEDBACK: SHARE DRAFTS WITH COLLEAGUES OR MENTORS.
- USE TEMPLATES: ADAPT PUBLISHED PROTOCOLS FOR YOUR TOPIC.
- PLAN FOR REVISIONS: BE PREPARED TO REFINE BASED ON PROSPERO OR JOURNAL FEEDBACK.



7. CHALLENGES & MITIGATION

- COMMON CHALLENGES:
 - TIME CONSTRAINTS: AVERAGE SR TAKES 12–18 MONTHS.
 - RESOURCE LIMITS: ACCESS TO PAID DATABASES (E.G., EMBASE).
 - DATA OVERLOAD: SCREENING 10,000+ PAPERS.
- SOLUTIONS:
 - COLLABORATION: COVIDENCE FOR TEAM SCREENING.
 - AUTOMATION: RAYYAN AI FOR DEDUPLICATION.
 - OPEN ACCESS: USE GOOGLE SCHOLAR, PREPRINT SERVERS.

8. RESOURCES & FURTHER READING

CONTENT:

- GUIDELINES:
 - EQUATOR NETWORK: HUB FOR REPORTING STANDARDS.
 - COCHRANE HANDBOOK: STEP-BY-STEP SR METHODOLOGY.
- TOOLS:
 - RAYYAN: AI-ASSISTED SCREENING.
 - COVIDENCE: COLLABORATIVE PLATFORM.
 - ZOTERO: REFERENCE MANAGEMENT.
- TRAINING:
 - COURSERA: "SYSTEMATIC REVIEW BASICS" (UNIVERSITY OF COPENHAGEN).
 - BOOKS: "FINDING WHAT WORKS IN HEALTH CARE" (IOM).

ek no.